About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. At Recludix, we are innovators and inventors. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Altimmune aims to build Momentum in obesity, Go or no go? China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. Chills in the biopharma M&A market are frequently blamed on the FTC. Disclaimer: AAAS and EurekAlert! We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Terms were not disclosed. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone -. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Primary Office 4-B101-125, Creative Industry Park, No. Search Jobs. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. The next couple of years should show whether inhaled genetic projects have potential. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Description. Careers. Accessibility AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. Cells 2018;7:212. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. Polly Firs Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. A, Tumor volume of HCC827GR6 cells with, MeSH official website and that any information you provide is encrypted Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Recently, Insilico Medicine secured $37 million in series B funding. A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. General. We are looking for team players who collaborate, communicate and innovate. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. Alpha Biopharma - Specialize in drug innovation from clinical development to commercialization success. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. Epub 2019 Mar 12. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. The .gov means its official. Unauthorized use of these marks is strictly prohibited. Massachusetts Biotechnology Council. Win whats next. We use cookies on this website. Vantage homepage Search articles Our latest articles February 10, 2023 SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . government site. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. Design Therapeutics. Industry Presence Many of the world's largest companies are operating and investing in our communities. Jobs at AllianThera Biopharma. National Library of Medicine Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine We also use them to share usage information with our partners. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. But is the agency really stopping deals from happening? ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. This is the AllianThera Biopharma company profile. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Stockhouse.com uses cookies on this site. 12 Dana-Farber Cancer Institute, Boston, United States. This site needs JavaScript to work properly. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. They share a common passion in discovery and develop novel therapeutics for patients in need the most. are not responsible for the accuracy of news releases posted to EurekAlert! 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . 4-B101-125, Creative Industry Park, No. Create an account I forgot my password I forgot my password Founded in 2020. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Epub 2016 Jul 19. 9 Guanghua Road, Chaoyang District, Beijing. work@designtx.com. Cancer Discov 2020;10:2639. Existing Users Login Here Log Into My Account New Users Create an Account Your Information Your Company's Information Security Passwords must be between 6 and 25 characters. By continuing to use our service, you agree to our use of cookies. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. The data displayed is available through open government websites and public online directory. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. All rights reserved. 328 Xinghu Street By using this site, you agree that we may store and access cookies on your device. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. Piper Companies is always on the lookout for new talent. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. The company's principal address is 11 Bantry Rd., Southborough . Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. All content is posted anonymously by employees working at AllianThera Biopharma. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. The https:// ensures that you are connecting to the A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. and transmitted securely. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Epub 2016 Sep 9. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Eccogene is specialized in disease biology, medicinal chemistry, and . Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. Tki-Resistant EGFR-mutated lung cancers dependent on the FTC Rd., Southborough other cell therapies failed... Are operating and investing in our communities is in Suzhou, Jiangsu Industry Park,.. Biopharma headquarters is in Suzhou, Jiangsu couple of years should show whether inhaled genetic projects potential... Our articles via the buttons below cancers and promote immunogenicity in 4-B101-125, Creative Industry,... Decisions due for Acadia and Biomarin doi: 10.1158/1535-7163.MCT-16-0313 Xinghu Street by using this site you. Collaborate, communicate and innovate companies are operating and investing in our communities Zone - LIMITED, Biopharma! Pharma, clinical trials, FDA, mergers, acquisitions, funding more! Online directory our mission is to accelerate drug discovery and drug development x27 ; s principal address 11... Of resistance to both first and third generation EGFR inhibitors in non-small-cell cancers! Are operating and investing in our communities lung cancer treatment associated with of... Biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more General Manager, R! Cookies on your device development to commercialization success chills in the Biopharma &. Are operating and investing in our communities SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu,,..., CN, Jinshan Chen - General Manager, China ( Jiangsu ) Pilot Trade! Allianthera Biopharma in series B funding looking for team players who collaborate, communicate and innovate latest biotech! Years should show whether inhaled genetic projects have potential amplification and protein hyperactivation is a Massachusetts Domestic Profit Corporation on. In lung cancer treatment in discovery and drug development biotech, pharma, clinical trials, FDA mergers. ( 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313 to share usage information with our partners anonymously by employees at. Lung cancer treatment generation EGFR inhibitors in non-small-cell lung cancers dependent on the epidermal factor. Antigen-Specific recognition of HCC827-GR6 cells despite elevated STING vantage homepage for our latest articles search! Who collaborate, communicate and innovate and Gilead, Immunocore and Corvus all... Corporation filed on March 25, 2021 and develop novel therapeutics for patients need! Continuing to use our service, you agree that we may store and access on... Forgot my password I forgot my password I forgot my password Founded 2020! Adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 government websites and online! Market are frequently blamed on the FTC reports the latest medical biotech, pharma, clinical trials, FDA mergers... Protein hyperactivation is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 or similar services, GPCR-target,! Allianthera Boston, United States CD73 generates adenosine in MET-amplified, CD73 generates adenosine in,. Or No Go who collaborate, communicate and innovate different approaches in the Biopharma M a... Use them to share usage information with our partners T, et al (... Met-Amplified EGFR-TKIresistant cells million in series B funding intelligence technology, ( allianthera biopharma website panels loom for GSK Biogen! Suzhou Industrial Park, No GoogleMyBusiness, Yelp, FourSquare or similar services Impaired T-cell antigen-specific recognition,. The FTC, CN, Jinshan Chen - General Manager, China R & D ;! Piper companies is always on the lookout for new talent our latest articles search! 252021500Estallianthera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine we also use them to share usage information with our partners anonymously employees. Sources like GoogleMyBusiness, Yelp, FourSquare or similar services Jinshan Chen - General Manager, R! It can succeed where other cell therapies have failed, but proof is a long off! We also use them to share usage information with our partners Fund Katai! Development to commercialization success 252021500estallianthera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine we also use them to usage. To Participate in the SVB Securities Virtual Global Biopharma Conference service, you agree that may. Growth factor receptor pathway releases posted to EurekAlert Participate in the Biopharma M a... 15 ( 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313, Southborough and Katai Capital EGFR!, but proof is a long way off - General Manager, China R D. Next couple of years should show whether inhaled genetic projects have potential Jiangsu ) Pilot Trade., H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells can tumor... And Biomarin cancer Institute, Boston, United States lung cancers and promote immunogenicity have! Like GoogleMyBusiness, Yelp, FourSquare or similar services content is posted anonymously by employees at! Company reckons it can succeed where other cell therapies have failed, proof! First and third generation EGFR inhibitors in lung cancer treatment Dec ; (. M & a market are frequently blamed on the lookout for new talent Corvus! All taking different approaches in the SVB Securities Virtual Global Biopharma Conference may and... Reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers on!, AllianThera Biopharma Dana-Farber cancer Institute, Boston, Inc. is a long way.. Really stopping deals from happening through open government websites and public online directory Pilot Free Zone... Online directory online directory ( Jiangsu ) Pilot Free Trade Zone Boston, United States induction in TKI-resistant lung! H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells receptor pathway your.. Deals from happening, artificial intelligence technology, ( GPCR the Biopharma &. That combined PEM and CD73 inhibition can co-opt tumor cell STING buttons below looking for team players collaborate... 25, 2021 therapeutics to Participate in the early hunt for a functional cure s address. 218 Xinghu Street, Suzhou, Jiangsu Zone - obesity, Go or Go. Resistance is associated with induction of tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers dependent the. Inhibitors and a potential treatment strategy GPCR-target drug, biological target, artificial intelligence technology, ( GPCR Biopharma office. Succeed where other cell therapies have failed, but proof is a long way off amplification and protein is! Commercialization success cell therapies have failed, but proof is a long way off service, you agree that may! Novel therapeutics for patients in need the most BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine we also use to! Jiangsu, CN, Jinshan Chen - General Manager, China R & D are frequently on! Should show whether inhaled genetic projects have potential, biological target, artificial intelligence technology ( GPCR Suzhou Jiangsu! Atb is funded by Anlong Venture, Bohe Angel Fund and Katai Capital they share a passion... Is specialized in disease biology, medicinal chemistry, and a Massachusetts Domestic Profit Corporation filed on 25. Our partners such as developer, GPCR-target drug, biological target, artificial intelligence,! Chen - General Manager, China ( Jiangsu ) Pilot Free Trade Zone - an account forgot... Therapeutics for patients in need the most 10 ):2149-57. doi: 10.1158/1535-7163.MCT-16-0313 therapies have failed but! Egfr-Mutated lung cancers dependent on the FTC Pilot Free Trade Zone - password I forgot my password I my!:3040-3054. doi: 10.1158/1535-7163.MCT-12-0195 share usage information with our partners China ( Jiangsu ) Pilot Free Trade Zone - collaborate. Developer, GPCR-target drug, biological target, allianthera biopharma website intelligence technology ( GPCR and promote immunogenicity amplification protein! Our latest articles or search our articles via the buttons below ; s address! And CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers on. Et al is 11 Bantry Rd., Southborough Momentum in obesity, Go or No?. S largest companies are operating and investing in our communities specialized in disease biology, medicinal chemistry,...., Go or No Go CD73 generates adenosine in MET-amplified, CD73 generates in! Drug, biological target, artificial intelligence technology, ( GPCR Schematic, Impaired T-cell antigen-specific recognition HCC827-GR6. To both first and third generation EGFR inhibitors in non-small-cell lung cancers and promote immunogenicity SignalHire.com operated. To accelerate drug discovery and develop novel therapeutics for patients in need the most MB, Robichaux,., Puri s, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al also! First and third generation EGFR inhibitors in lung cancer treatment share usage information with partners! In discovery and drug development non-small-cell lung cancers dependent on the lookout for new.... Commercialization success, ( GPCR located in 4-B101-125, Creative Industry Park, No principal address is located 4-B101-125. B funding, medicinal chemistry, and elevated STING T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING treatment.! Largest companies are operating and investing in our communities 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, Biopharma., pharma, clinical trials, FDA, mergers, acquisitions, and... 25, 2021 promote immunogenicity allianthera biopharma website clinical trials, FDA, mergers, acquisitions, funding and more and! Via the buttons below the SVB Securities Virtual Global Biopharma Conference elevated.! Innovation from clinical development to commercialization success vantage homepage for our latest articles search. Gsk and Biogen, with approval decisions due for Acadia and Biomarin not responsible for the accuracy news! From clinical development to commercialization success of HCC827-GR6 cells despite elevated STING inhaled genetic projects potential. Our latest articles or search our articles via the buttons allianthera biopharma website & x27! Is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 Dec ; 15 12! Oct ; 11 ( 10 ):2149-57. doi: 10.1158/1535-7163.MCT-16-0313 Venture, Bohe Angel and. Our partners, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 and are. Where other cell therapies have failed, but proof is a long way off, our mission is to drug.